Search
for

    Glossary BRAF inhibitors

    drugs that block mutated BRAF protein to treat cancer

    BRAF inhibitors are a class of drugs designed to block the activity of the BRAF protein, which is involved in sending signals inside cells and can contribute to cancer growth when mutated. These inhibitors are particularly used in treating certain types of melanoma and other cancers with specific BRAF mutations, helping to slow down or stop the progression of the disease.

    Related Terms

    Research 10 of 355

    1. BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer Thyroid · 2014 · 188 citations
    2. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. Journal of the European Academy of Dermatology and Venereology · 2014 · 31 citations
    3. Network pharmacology and molecular docking analysis on potential molecular targets and mechanism of action of BRAF inhibitors for application in wound healing Journal of Cellular Biochemistry · 2023 · 11 citations
    4. The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma Current Dermatology Reports · 2013 · 6 citations
    5. Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects PLOS ONE · 2021 · 3 citations
    6. Melanotic pigmentation in excisional scar of melanoma patient who received BRAF and MEK inhibitors Journal of The American Academy of Dermatology · 2018 · 1 citations
    7. 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes Journal of Investigative Dermatology · 2016
    8. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma British Journal of Dermatology · 2012 · 173 citations
    9. Abstract 1677: Epithelial hyperplasia induced by a selective B-Raf inhibitor, WYE-130600 Cancer Research · 2010 · 1 citations
    10. 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma Journal of Investigative Dermatology · 2016
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →